Google+ Facebook Twitter Twitter

Tech news: May

This month's top tech news stories


Antigen testing

LGC has released ACCURUN SARS-CoV-2 Antigen Reference Material Kit, a new quality measurement tool to support SARS-CoV-2 antigen testing.

It is formulated for use with test methods that detect the nucleocapsid (NP) protein of SARS-CoV-2 virus – the target for the majority of the SARS-CoV-2 antigen assays currently on the market. The product comprises purified recombinant SARS-CoV-2 NP protein in simulated viral transport media.




CDI Labs, a biotechnology company in Puerto Rico, is using INTEGRA’s VIAFLO and VOYAGER electronic pipettes to streamline workflows and improve accuracy for the development of next generation proteomics products.

The company, well known for the HuProt Human Proteome Microarray, has expanded its portfolio to include a catalogue of over 2000 monoclonal antibodies designed to accelerate research that improves human health.


Menarini Diagnostics

Specific Serology

Menarini Diagnostics is expanding its comprehensive COVID testing portfolio with an automated SARS-CoV-2 Neutralising Antibodies (NAb) test.

The CE-IVD marked immunoassay is performed on the eCL8000 benchtop ECLIA platform, capable of 86 test results per hour.

The SARS-CoV-2 NAb assay has been specifically designed to match the performance of plaque reduction methodology whilst maintaining the convenience of routine serological analysis.

Quantification of NAbs is the best way to determine immune status post-vaccination or infection.

Image credit | iStock


Related Articles

All-in-one Covid surveillance test

A new type of COVID-19 testing strategy could help streamline the process of identifying cases, tracking variants and detecting co-infecting viruses, it is claimed.

Ultra-sensitive rapid diagnostic for Ebola

An interdisciplinary team of scientists has developed a highly sensitive and rapid diagnostic test for Ebola virus (EBOV) infection.

Novel Covid test

A new rapid test has been developed that is 98.3% accurate for positive COVID-19 tests and 96% for negative tests.